Faron Pharmaceuticals Oy (FARN) — Cash Flow-to-Debt Ratio
Faron Pharmaceuticals Oy (FARN) has a Cash Flow-to-Debt Ratio of 0.00x as of June 2025, meaning its operating cash flow of GBX-5.21K could theoretically repay 0% of its total liabilities (GBX32.45 Million) in one year. See cash generation quality of Faron Pharmaceuticals Oy to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Faron Pharmaceuticals Oy Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Faron Pharmaceuticals Oy across 13 annual periods. Also explore FARN net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Faron Pharmaceuticals Oy (2012–2024)
Year-by-year debt coverage analysis for Faron Pharmaceuticals Oy. For market capitalisation and broader financial context, see Faron Pharmaceuticals Oy stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.03x | GBX-22.97 Million | GBX22.28 Million | ▼ -9.9% |
| 2023 | -0.94x | GBX-23.81 Million | GBX25.38 Million | ▲ +7.2% |
| 2022 | -1.01x | GBX-22.99 Million | GBX22.75 Million | ▲ +53.3% |
| 2021 | -2.16x | GBX-22.22 Million | GBX10.26 Million | ▼ -26.5% |
| 2020 | -1.71x | GBX-17.48 Million | GBX10.22 Million | ▼ -27.7% |
| 2019 | -1.34x | GBX-11.52 Million | GBX8.60 Million | ▼ -49734.5% |
| 2018 | 0.00x | GBX-20.52K | GBX7.63 Million | ▲ +99.9% |
| 2017 | -1.81x | GBX-18.36 Million | GBX10.14 Million | ▼ -37.2% |
| 2016 | -1.32x | GBX-8.45 Million | GBX6.40 Million | ▲ +32.7% |
| 2015 | -1.96x | GBX-7.15 Million | GBX3.64 Million | ▼ -1590.8% |
| 2014 | -0.12x | GBX-389.00K | GBX3.35 Million | ▲ +51.9% |
| 2013 | -0.24x | GBX-768.00K | GBX3.19 Million | ▲ +70.5% |
| 2012 | -0.82x | GBX-2.27 Million | GBX2.77 Million | — |